Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 67Triple Negative Breast Neoplasms 16Neoplasm Metastasis 9Sarcoma 6Ovarian Neoplasms 4Brain Neoplasms 4Neoplasms 3Liposarcoma 3Inflammatory Breast Neoplasms 3HER2-negative Breast Cancer 3Leiomyosarcoma 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Salivary Gland Neoplasms 1Relapsed Solid Tumors 1Refractory Solid Tumors 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Neoplasm, Residual 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Ketosis 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1HER2-negative Metastatic Breast Cancer 1

Interventions

pazopanib 2Ifosfamide 2Doxorubicin 2tremelimumab 1selinexor 1eribulin 1durvalumab 1Sunitinib 1Proton Therapy 1Nivolumab 1Methotrexate 1Gemcitabine 1Epirubicin 1Dacarbazine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hemangioendothelioma, Epithelioid × eribulin × Clear all
NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Massachusetts General Hospital

Phase 2 Active not recruiting
13 enrolled 9 charts
Sarcoma

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡